The content on this site is intended for healthcare professionals only
Dr Mariana Chavez McGregor, speaks to ecancer at the Best of ASCO®️ 2024 Miami Symposium about antibody drug conjugates and how they have changed the treatment of patients with breast cancer, and how to best integrate them into treatments.
She emphasises the swift advancements in antibody-drug conjugates, predicting an increase in data on this approach in the coming years. As this method is applied earlier and new information on other drugs emerges, the process of selecting and sequencing treatments is expected to improve.
Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer
Hormonal receptor positive breast cancer adjuvant and metastatic indications
Comment: EBCC 2024 highlights
Low-dose olanzapine after highly emetogenic chemotherapy can be the new standard of care for solid tumours
Breast Cancer
OncoAlert Round Up for August 11th - 17th, 2023
Hodgkin’s and non-Hodgkin’s lymphomas (NHL)
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
The role of CDK4/6 inhibitors in the treatment of metastatic breast cancer
